Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now

Frankfurt - Delayed Quote EUR

Incyte Corporation (ICY.F)

Compare

66.78

-3.56

(-5.06%)

As of 8:01:25 AM GMT+1. Market Open.

Is Incyte Corporation (INCY) The Best Immunology Stock To Buy Now?

We recently published a list of 10 Best Immunology Stocks To Buy Now. In this article, we are going to take a look at where Incyte Corporation (NASDAQ:INCY) stands against other best immunology stocks to buy now. The Growing Market for Immune System Treatments Immunology is a rapidly advancing field with significant potential for growth, […]

Insider Monkey 2 days ago

INCY
Incyte to Unveil New Data from its Dermatology Portfolio at 2025 American Academy of Dermatology (AAD) Annual Meeting

WILMINGTON, Del., February 28, 2025--Incyte to Unveil New Data from its Dermatology Portfolio at 2025 American Academy of Dermatology (AAD) Annual Meeting

Business Wire 4 days ago

INCY
High Growth Tech Stocks to Watch in US Market February 2025

Over the last 7 days, the United States market has dropped 4.8%, yet it remains up by 15% over the past year with earnings forecast to grow by 14% annually. In this context, identifying high growth tech stocks involves looking for companies that can capitalize on technological advancements and maintain robust growth trajectories despite short-term market fluctuations.

Simply Wall St. 4 days ago

BIGC

HRTX

INCY
Incyte Corporation (INCY) Partners with Genesis AI to Accelerate Drug Discovery

We recently published a list of 12 AI Updates Worth Taking a Look At. In this article, we are going to take a look at where Incyte Corporation (NASDAQ:INCY) stands against other AI updates worth taking a look at. AI’s Expanding Role in Carbon Up-Valuing and Biopharma Development In a Bloomberg interview, SandboxAQ CEO Jack […]

Insider Monkey 7 days ago

INCY
Incyte and Genesis collaborate on small-molecule medicines

Genesis will obtain a $30m upfront payment and the collaboration will initially focus on two targets.

Pharmaceutical Technology 11 days ago

INCY
Incyte and Genesis Therapeutics Announce Strategic AI-focused Research Collaboration

WILMINGTON, Del. & BURLINGAME, Calif., February 20, 2025--Incyte and Genesis Therapeutics announce strategic AI-focused research collaboration

Business Wire 12 days ago

INCY
Incyte Stock Sees Relative Strength Rating Rise To 71

Incyte stock saw a welcome improvement to its Relative Strength (RS) Rating on Tuesday, with an increase from 67 to 71. See if Incyte stock can continue to rebound and hit that benchmark. Is Incyte Stock A Buy?

Investor's Business Daily 13 days ago

INCY

HALO

CORT
Incyte to Present at Upcoming Investor Conferences

WILMINGTON, Del., February 18, 2025--Incyte (Nasdaq:INCY) announced today that it will present at the following investor conferences during the month of March:

Business Wire 14 days ago

INCY
3 US Stocks Estimated To Be 14.6% To 47.8% Below Intrinsic Value

As the U.S. stock market edges close to record highs, buoyed by positive wholesale inflation data and a stable tariff environment, investors are increasingly on the lookout for opportunities that may be trading below their intrinsic value. In this context, identifying undervalued stocks becomes crucial as these investments can offer potential upside in a market where major indices have recently posted weekly gains.

Simply Wall St. 15 days ago

INSP

DUOL

INCY
Incyte Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags

Incyte ( NASDAQ:INCY ) Full Year 2024 Results Key Financial Results Revenue: US$4.24b (up 15% from FY 2023). Net...

Simply Wall St. 21 days ago

INCY
Incyte Corp (INCY) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Outlook

Incyte Corp (INCY) reports a 15% revenue increase for 2024, driven by robust sales of Jakafi and Opzelura, while maintaining a solid cash position and outlining ambitious 2025 guidance.

GuruFocus.com 21 days ago

INCY
Q4 2024 Incyte Corp Earnings Call

Q4 2024 Incyte Corp Earnings Call

Thomson Reuters StreetEvents 21 days ago

INCY
S&P 500 Gains and Losses Today: Supermicro Stock Surges Ahead of Business Update

The S&P 500 gained 0.7% on Monday, Feb. 10, as investors weighed the impact of additional tariffs on imported metals and awaited more earnings updates.

Investopedia 21 days ago

^GSPC

SMCI

WDC
Incyte Reports 2024 Financial Results and Outlines 2025 Projections

$1.2 billion in Q4 2024, a 16% year-over-year increase; $4.2 billion for the full year, up 15% from 2023.

GuruFocus.com 21 days ago

INCY
Why Incyte (INCY) Shares Are Plunging Today

Shares of biopharmaceutical company Incyte Corporation (NASDAQ:INCY) fell 8.9% in the morning session after the company reported fourth-quarter results with full-year guidance for key products such as Jakafi and Opzelura, indicating a significant deceleration in growth. Also, earnings fell short of expectations during the quarter, suggesting profit might be under pressure. On the other hand, revenue exceeded expectations, but markets tend to focus more on the long term. Overall, this quarter cou

StockStory 21 days ago

INCY
Incyte Stock Sinks as Sales Forecast for Key Drugs Falls Short

Incyte stock was one of the biggest decliners on the S&P 500 Monday after the drugmaker's fourth-quarter adjusted profit and projections for 2025 sales of key medications fell short of analysts' estimates.

Investopedia 21 days ago

INCY
INCY's Q4 Earnings Miss Mark, Revenues Beat on Higher Product Sales

Incyte reports mixed fourth-quarter 2024 results as earnings miss estimates while revenues beat the same. Jakafi and Opzelura drive year-over-year sales.

Zacks 22 days ago

INCY

LLY
Incyte Q4 Earnings: EPS Miss, Strong Jakafi And Opzelura Sales, Says 2025 To Be Catalyst Rich Including 4 Launches

On Monday, Incyte Corporation (NASDAQ:INCY) reported fourth-quarter revenue of $1.18 billion, up 16% year over year and beating the consensus of $1.14 billion. The company reported an adjusted EPS of $1.43, which was up from $1.06 a year ago and missing the consensus estimate of $1.56. Jakafi’s net product revenue increased 11% to $773.1 million, primarily due to a 14% increase in paid demand. Also Read: Incyte At JPM25: Eyes Transformational 2025 With Multiple Drug Launches And Expanding Pipeli

Benzinga 22 days ago

INCY
Incyte (INCY) Reports Q4 Earnings: What Key Metrics Have to Say

Although the revenue and EPS for Incyte (INCY) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Zacks 22 days ago

INCY
Incyte forecasts downbeat annual sales of skin disease drug, shares fall

(Reuters) -Incyte Corp on Monday forecast annual sales of its skin disorder treatment Opzelura below Wall Street estimates, sending the drugmaker's shares down as much as 9% in afternoon trade. Opzelura is used for the treatment of skin conditions called vitiligo and mild-to-moderate atopic dermatitis in patients 12 years and older. Incyte expects Opzelura sales in 2025 to be between $630 million and $670 million.

Reuters 22 days ago

INCY

Performance Overview

Return	ICY.F	S&P 500
YTD	+1.12%	-2.27%
1-Year	+22.44%	+12.03%
3-Year	+5.00%	+32.79%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Incyte Corporation (ICY.F)

Is Incyte Corporation (INCY) The Best Immunology Stock To Buy Now?

Incyte to Unveil New Data from its Dermatology Portfolio at 2025 American Academy of Dermatology (AAD) Annual Meeting

High Growth Tech Stocks to Watch in US Market February 2025

Incyte Corporation (INCY) Partners with Genesis AI to Accelerate Drug Discovery

Incyte and Genesis collaborate on small-molecule medicines

Incyte and Genesis Therapeutics Announce Strategic AI-focused Research Collaboration

Incyte Stock Sees Relative Strength Rating Rise To 71

Incyte to Present at Upcoming Investor Conferences

3 US Stocks Estimated To Be 14.6% To 47.8% Below Intrinsic Value

Incyte Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags

Incyte Corp (INCY) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Outlook

Q4 2024 Incyte Corp Earnings Call

S&P 500 Gains and Losses Today: Supermicro Stock Surges Ahead of Business Update

Incyte Reports 2024 Financial Results and Outlines 2025 Projections

Why Incyte (INCY) Shares Are Plunging Today

Incyte Stock Sinks as Sales Forecast for Key Drugs Falls Short

INCY's Q4 Earnings Miss Mark, Revenues Beat on Higher Product Sales

Incyte Q4 Earnings: EPS Miss, Strong Jakafi And Opzelura Sales, Says 2025 To Be Catalyst Rich Including 4 Launches

Incyte (INCY) Reports Q4 Earnings: What Key Metrics Have to Say

Incyte forecasts downbeat annual sales of skin disease drug, shares fall

Performance Overview